IDIBELL on the media

20171003_Ballestar_CellReports_0

IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients

The tumoral microenvironment subverts immune cell function A key regulator of myeloid derived suppressor cells and the possibility of reverting its effects on immune fucntion Article citation

20170927_Campus_ExpoCurie_0

El Campus de Bellvitge acoge la exposición ‘María Sklodowska-Curie, una polaca en París’

Una muestra para reivindicar la figura de Marie Curie María Sklodowska-Curie

20170922_OTRI_H2020_1

Success of the “H2020 Opportunities” informative session

On September 21st, an “Oportunidades en H2020 SC1 2018-20” workshop was held in the Pau Viladiu hall of Duran i Reynals Hospital. This session was jointly organized by IDIBELL’s Research Support Office and ICO’s Research Management Unit on the occasion of the imminent opening of calls for the Work Program of the H2020 Social Challenge […]

Communiqué from the universities and research centres of Catalonia

Today, the highest representatives of the universities and research centres of Catalonia (60 institutions, representing around 90% of the university and research community) have met to assess the current situation in Catalonia resulting from the actions of the Spanish Government over the last few days. The meeting was also attended by representatives of the trade […]

20170913_Pujana_LAM_1

A group of lymphangioleiomyomatosis (LAM) patients attend a talk on the disease and advances

David J. Kwiatkowski, a professor of medicine at Harvard University and an oncologist specializing in thoracic oncology at Dana-Farber Cancer Institute in Boston, was responsible for explaining the advances in genetics and clinical trials being conducted to combat the disease What is LAM?

20170801_Ceron_Fdez_INPhINIT

IDIBELL will foster three INPhINIT young researchers

The INPhINIT doctoral grants from La Caixa Obra Social will allow IDIBELL to offer a three-year contract to the researchers

20170731_IDIBELL_CataLands

El Grupo CataLands Solidaris da 10.000 euros al Programa ProCURE

El dinero recogido servirá para desarrollar un proyecto de inmunoterapia que lideran los investigadores Ramon Alemany y Josep Mª Piulats Fin de Semana Solidario del Automóvil en Llinars Quienes son los CataLands Solidaris?

20170718_idibell_bib

IDIBELL joins the Barcelona Bioinformatics Association

The Bellvitge Biomedical Research Institute (IDIBELL) has officially joined the Bioinformatics Barcelona Association (BIB), a non-profit organization focused on the development of the field of bioinformatics in Catalonia. Established in 2015, the BIB currently comprises 53 major institutions related to the bioinformatics sector – universities, research centers, hospitals, major scientific infrastructures, companies and other partners. […]

20170714_Esteller_Carlemany

Dr. Manel Esteller receives the Falcó Carlemany Award

Manel Esteller, director of the epigenetics and cancer biology program at IDIBELL, ICREA researcher and professor at the University of Barcelona has been awarded the Falcó Carlemany Award for the social impact of his cancer research. The Falcó Carlemany Award is awarded to a person or entity for their contributions to relevant, high-impact social projects. […]

20170710_Garcia_Mollevi

Nova eina d’anàlisi per a predir la resposta al tractament preoperatori en càncer de recte

Investigadors del Programa Contra la Resistència Terapèutica del Càncer (ProCURE), de l’Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) i de l’Institut Català d’Oncologia (ICO) han desenvolupat una nova eina que permet establir la probabilitat de resposta al tractament preoperatori en tumors de recte localment avançats. Predir quins pacients no respondran al tractament pot ajudar a evitar […]

Scroll to Top